Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln

Emergent BioSolutions

10/03/2025 17:24

** Shares of drugmaker Emergent BioSolutions EBS.N fall 3% to $5.60, hit nine-month low

** India's Syngene International SYNN.NS says it has acquired its first biologics facility in the U.S. from Emergent Manufacturing Operations Baltimore, a unit of EBS, for $36.5 million

** The deal is expected to close in March, 2025

** Co says the facility is expected to be operational for client projects from the H2 2025

** Up to last close, EBS has risen more than double in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))